Myrto Christofidou
Overview
Explore the profile of Myrto Christofidou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Drogari-Apiranthitou M, Skiada A, Panayiotides I, Vyzantiadis T, Poulopoulou A, Christofidou M, et al.
J Fungi (Basel)
. 2023 Apr;
9(4).
PMID: 37108880
Mucormycosis has emerged as a group of severe infections mainly in immunocompromised patients. We analysed the epidemiology of mucormycosis in Greece in a multicentre, nationwide prospective survey of patients of...
2.
Spiliopoulou A, Kyriakou G, Georgiou S, Lekkou A, Leonidou L, Militsopoulou M, et al.
Rev Inst Med Trop Sao Paulo
. 2023 Apr;
65:e29.
PMID: 37075336
Acid-fast bacteria can be implicated in skin and soft tissue infections. Diagnostic identification can be challenging or not feasible by routine laboratory techniques, especially if there is no access to...
3.
Spiliopoulou A, Lekkou A, Vrioni G, Leonidou L, Cogliati M, Christofidou M, et al.
J Mycol Med
. 2023 Apr;
33(3):101386.
PMID: 37031651
Introduction: Non-Candida yeasts, although rare, are increasingly encountered and recognized as a growing threat. Methods: Cases of bloodstream infections (BSIs) due to non-Candida yeasts (NCYs) during the last four years...
4.
Mpakosi A, Siopi M, Vrioni G, Orfanidou M, Argyropoulou A, Christofidou M, et al.
Mycopathologia
. 2022 Sep;
187(5-6):439-453.
PMID: 36178544
In a multicenter, prospective study of filamentous fungal keratitis in Greece, predisposing factors, etiology, treatment practices, and outcome, were determined. Corneal scrapings were collected from patients with clinical suspicion of...
5.
Papadimitriou-Olivgeris M, Spiliopoulou A, Fligou F, Tsiata E, Kolonitsiou F, Nikolopoulou A, et al.
J Med Microbiol
. 2021 Aug;
70(8).
PMID: 34431765
Resistance rates to azoles and echinocandins of spp. increased over the last decade. Widespread use of antifungals could lead to development and dissemination of resistant spp. To identify risk factors...
6.
Papadimitriou-Olivgeris M, Bartzavali C, Georgakopoulou A, Kolonitsiou F, Papamichail C, Spiliopoulou I, et al.
Antibiotics (Basel)
. 2021 Jan;
10(1).
PMID: 33467394
Background: The increased frequency of bacteraemias caused by pandrug-resistant
(PDR-Kp) has significant implications. The aim of the present study was to identify predictors associated with mortality of PDR-Kp bacteraemias. Methods:...
7.
Papadimitriou-Olivgeris M, Bartzavali C, Georgakopoulou A, Kolonitsiou F, Mplani V, Spiliopoulou I, et al.
Clin Microbiol Infect
. 2021 Jan;
27(6):915.e1-915.e3.
PMID: 33444757
Objectives: Our aim was to validate the INCREMENT-CPE score (ICS) in patients hospitalized in the intensive care unit (ICU) with bacteraemia due to carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Methods: The study...
8.
Papadimitriou-Olivgeris M, Bartzavali C, Nikolopoulou A, Kolonitsiou F, Mplani V, Spiliopoulou I, et al.
Antibiotics (Basel)
. 2020 Nov;
9(11).
PMID: 33228012
Background: Tigecycline is a therapeutic option for carbapenemase-producing (CP-Kp). Our aim was to evaluate the impact of the tigecycline's minimum inhibitory concentration (MIC) in the outcome of patients with CP-Kp...
9.
Assimakopoulos S, Lazaris V, Papadimitriou-Olivgeris M, Lagadinou M, Verigou E, Tzouvara E, et al.
Infect Dis (Lond)
. 2020 Mar;
52(6):446-449.
PMID: 32208860
No abstract available.
10.
Hamel M, Chatzipanagiotou S, Hadjadj L, Petinaki E, Papagianni S, Charalampaki N, et al.
Int J Antimicrob Agents
. 2020 Mar;
55(4):105930.
PMID: 32130981
Introduction: In Greece, the spread of carbapenem-resistant Enterobacteriaceae in humans has led to the reintroduction of colistin as a therapeutic agent. Unfortunately, colistin resistance with different mechanisms has emerged. The...